Latest News
Inhalon Biopharma to Present Poster on IN‑007 at RDD 2026
Durham, North Carolina, May 8, 2026 — Inhalon Biopharma (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced that it will present results from aerosolization studies of IN‑007, a potential treatment for all strains of SARS-CoV-2, at the Respiratory Drug Delivery (RDD®) 2026 conference May10-14, 2026, held in Phoenix, Arizona.
Inhalon Biopharma is developing inhaled antibody therapeutics as potential treatments for a range of acute respiratory infections, such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and influenza.
The company’s platform delivers proprietary muco-trapping monoclonal antibodies directly to the airways via a handheld nebulizer, physically crosslinking respiratory viruses to secreted airway mucins and physically eliminating the viruses from the lung through the natural mucus clearance. In a Phase 1b clinical trial, inhaled dosing achieved vastly superior delivery to all parts of the respiratory tract compared to intravenous administration, validating Inhalon's core premise and vision to transform care for respiratory infections by enabling safe, effective, convenient, self-administered, outpatient treatments.
Poster Session Details
Poster Title: Stability and Aerosol Characterization of ACE-2 Decoy Antibody using a Vibrating Mesh Nebulizer
Session Title: Aqueous Advances
Session Date & Time: May 11 and 12, 2026, noon to 2pm MST
About Inhalon Biopharma
Inhalon Biopharma, Inc. is a private, clinical-stage company advancing a first-in-class inhaled antibody platform for treating a range of acute respiratory infections. Inhalon Biopharma’s intellectual property includes U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Cambrian Growth Partners, Berkeley Catalyst Fund, JSR Life Sciences, and Life Science Angels, as well as numerous grants and contracts from the NIH and USAMRDC.
Contact
John Whelan